Target Name: ZMYND10
NCBI ID: G51364
Review Report on ZMYND10 Target / Biomarker Content of Review Report on ZMYND10 Target / Biomarker
ZMYND10
Other Name(s): Ciliary dyskinesia, primary, 22 | ZMY10_HUMAN | dynein axonemal assembly factor 7 | Zinc finger MYND domain-containing protein 10 | zinc finger MYND-type containing 10 | tumor suppressor BLU | CILD22 | protein BLu | Protein BLu | BLU | DNAAF7 | FLU | Zinc finger MYND domain-containing protein 10 (isoform 1) | ZMYND10 variant 1 | Zinc finger MYND-type containing 10, transcript variant 1

CD-Related Protein ZMYND10: A Potential Drug Target

Ciliary dyskinesia (CD) is a rare, progressive genetic disorder that affects the movement of the small muscles in the cilia, which are the filtering structures that line the airways of the lungs. CD is typically diagnosed in infancy or early childhood and is characterized by the progressive development of characteristic clinical symptoms, such as coughing, wheezing, and difficulty breathing.

ZMYND10 is a gene that has been identified as a potential drug target for CD. The gene encodes a protein known as ZMYND10, which is involved in the formation of cilia. ZMYND10 is a transmembrane protein that is expressed in the ciliated epithelial cells that line the airways of the lungs.

CD is a genetic disorder that is caused by mutations in the ZMYND10 gene. The mutations have been shown to alter the structure and function of the ZMYND10 protein, leading to the development of CD-related symptoms.

Research has shown that ZMYND10 is a key regulator of the ciliature, which is the process by which the cilia move to remove foreign particles and bacteria from the airways of the lungs. The ciliature is critical for protecting the lungs from infection and inflammation.

In addition to its role in the ciliature, ZMYND10 has also been shown to be involved in the regulation of cell signaling pathways that are important for the development and maintenance of epithelial cells. These signaling pathways are important for the formation and function of the cilia, which are derived from epithelial cells.

The identification of ZMYND10 as a potential drug target for CD is based on several different lines of evidence. First, there is a strong body of evidence to suggest that CD is a progressive, inherited disorder that is characterized by the progressive development of characteristic symptoms. This is consistent with the hypothesis that ZMYND10 is a gene that is involved in the development of CD.

Second, there is evidence to suggest that ZMYND10 is involved in the regulation of the ciliature, which is critical for the function of the lungs. This is consistent with the hypothesis that ZMYND10 is a gene that is involved in the development and maintenance of the cilia.

Third, there is evidence to suggest that ZMYND10 is involved in the regulation of cell signaling pathways that are important for the development and maintenance of epithelial cells. This is consistent with the hypothesis that ZMYND10 is a gene that is involved in the development and maintenance of the epithelial cells that line the airways of the lungs.

In conclusion, ZMYND10 is a gene that has been identified as a potential drug target for CD. The evidence to support this identification comes from several different sources, including the identification of ZMYND10 as a key regulator of the ciliature and the regulation of cell signaling pathways that are important for the development and maintenance of epithelial cells. Further research is needed to determine the exact role of ZMYND10 in CD and to develop effective treatments for this progressive, inherited disorder.

Protein Name: Zinc Finger MYND-type Containing 10

Functions: Plays a role in axonemal structure organization and motility (PubMed:23891469, PubMed:23891471). Involved in axonemal pre-assembly of inner and outer dynein arms (IDA and ODA, respectively) for proper axoneme building for cilia motility (By similarity). May act by indirectly regulating transcription of dynein proteins (By similarity)

The "ZMYND10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZMYND10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZMYND11 | ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202 | ZNF204P | ZNF205 | ZNF205-AS1 | ZNF207 | ZNF208 | ZNF209P | ZNF211 | ZNF212 | ZNF213 | ZNF213-AS1 | ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254